Munich Cancer Registry

- Baseline statistics
- Selection Matrix
- Homepage
- *Deutsch*

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

C18.1: Appendix cancer

Year of diagnosis	1988-2012
Patients	553
Diseases	553
Cases evaluated	291
Creation date	03/25/2014
Export date	02/12/2014
Population	4.5 m

http://www.tumorregister-muenchen.de/en/facts/surv/surv_C181_E.pdf



Figure 1a. Relative survival of patients with appendix cancer by period of diagnosis. Included in the evaluation are 291 cases diagnosed between 1988 and 2012.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1988, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis			
	1988-1997 n=55		1998+ n=236	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	85.5	87.5	88.8	90.4
2	76.4	80.0	83.9	86.0
3	70.9	75.4	79.9	83.9
4	67.3	72.6	76.6	81.3
5	67.3	72.6	72.6	78.8
6	67.3	72.6	72.6	78.8
7	63.5	71.8	66.1	73.7
8	61.7	69.5	64.6	72.1
9	59.8	69.2	62.4	71.3
10	59.8	69.1	62.4	70.4

Table 1b. Observed (obs.) and relative (rel.) survival of patients with appendix cancer by period of diagnosis for period 1988-2012 (N=291).



Figure 2a. Survival of patients with appendix cancer by gender. Included in the evaluation are 291 cases diagnosed between 1988 and 2012.

	Gender			
	Male n=148		Female n=143	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	89.7	91.1	86.6	88.4
2	80.7	83.4	84.1	86.3
3	79.0	82.6	76.7	81.1
4	73.5	77.9	75.7	80.3
5	72.5	77.9	70.6	76.8
6	72.5	77.9	70.6	76.4
7	66.5	75.2	65.7	72.8
8	64.6	72.5	64.0	71.0
9	62.7	72.2	61.9	70.5
10	62.7	72.1	61.9	70.2

Table 2b. Observed (obs.) and relative (rel.) survival of patients with appendix cancer by gender for period 1988-2012 (N=291).



Figure 3a. Relative survival of patients with appendix cancer by age category. Included in the evaluation are 291 cases diagnosed between 1988 and 2012.



Figure 3b. Observed survival of patients with appendix cancer by age category. Included in the evaluation are 291 cases diagnosed between 1988 and 2012.

	Age category									
	0-49 yrs n=108		50-59 yrs n=50		60-69 yrs n=62		70-79 yrs n=40		80+ yrs n=31	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.1	97.1	85.8	85.4	86.9	87.4	89.9	90.7	61.1	66.8
2	94.9	94.9	79.0	79.0	83.4	84.0	79.0	83.5		
3			74.1	74.8	81.5	83.2	65.8	70.8		
4			68.7	70.2	79.1	81.7	54.9	63.1		
5			68.7	69.0	73.6	79.6	54.9	63.1		

Table 3c. Observed (obs.) and relative (rel.) survival of patients with appendix cancer by age category for period 1988-2012 (N=291).



Figure 4a. Relative survival of patients with appendix cancer by UICC. For 219 of 291 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 201 cases an evaluable classification was established. The grey line represents the subgroup of 90 patients with missing values regarding UICC (30.9% of 291 patients, the percent values of all other categories are related to n=201).

	UICC									
	I		II		III		IV		NA/NOS	
	n=48		n=63		n=31		n=59		n=90	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.9	97.1	98.4	98.5	90.3	92.0	62.7	64.0	92.1	93.0
2	92.4	93.3	94.9	98.5	80.1	83.4	47.1	47.4	92.1	93.0
3	92.4	92.0	94.9	98.5	64.9	69.7	40.2	42.2	88.3	91.3
4	84.1	87.8	92.6	98.5	64.9	67.6			86.9	90.1
5	84.1	87.0	89.7	98.5					85.4	89.7

Table 4b. Observed (obs.) and relative (rel.) survival of patients with appendix cancer by UICC for period 1988-2012 (N=201).



Figure 4c. Relative survival of patients with appendix cancer by TNM staging. For 291 of 291 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 276 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 15 patients with missing values regarding TNM staging (5.2% of 291 patients, the percent values of all other categories are related to n=276).

	TNM staging													
	T1+2 n=167		T3+4 n=143		N0 n=110		N+ n=61		M0 n=84		M1 n=59		NA/NOS n=15	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	91.5	92.8	83.8	86.0	97.3	98.0	73.7	75.5	97.6	98.9	62.7	64.0	100.0	93.4
2	88.9	91.5	74.5	77.8	93.2	96.2	55.7	57.2	94.9	98.5	47.1	47.4		
3	84.7	88.9	68.1	73.1	90.7	95.4	45.8	48.4	91.7	97.7	40.2	42.2		
4	81.6	86.8	64.0	69.6	86.7	92.4	41.9	44.0	88.1	95.2				
5	79.9	86.0	59.2	66.6	85.0	92.2	39.5	43.0	84.0	92.8				

Table 4d. Observed (obs.) and relative (rel.) survival of patients with appendix cancer by TNM staging for period 1988-2012 (N=624).



Figure 5a. Observed post-progression survival of 81 patients with appendix cancer diagnosed between 1988 and 2012 (incl. M1). These 81 patients with documented progression events during their course of disease represent 27.8% of the totally 291 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=11, 3.8%). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only

progression type during the course of disease. Subgroups with sample size <15 are dropped from the chart.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “All types” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	Type of progression			
	All types	Distant metastasis	Locoregional progress	NOS
	n=81	n=78	n=14	n=2
Months	%	%	%	%
0	100.0	100.0	100.0	100.0
12	66.2	66.2		
24	50.5	51.4		
36	42.0	42.4		
48	34.7	34.7		
60	30.7			

Table 5b. Observed post-progression survival of patients with appendix cancer for period 1988-2012 (N=81).

Shortcuts

AS	Assembled survival chart (observed, expected, relative)
CS	Conditional survival
DCO	Death certificate only. The death certificate provides the only notification to the registry.
MCR	Munich Cancer Registry, Germany (Tumorregister München)
NA	Not available
NCI	National Cancer Institute, USA
NOS	Not otherwise specified
OS	Observed/overall survival (Kaplan-Meier estimate)
PPS	Post-progression survival
RS	Relative Survival. Ratio of observed and expected survival (derived from the normal population)
SEER	Surveillance, Epidemiology, and End Results, USA
TTP	Time to progression Date of entry: Date of diagnosis Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified recurrence First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate). First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where applicable (“reverse” Kaplan-Meier estimate).
UICC	Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C18.1: Appendix cancer [Internet]. 2014 [updated 2014 Mar 25; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C181_E.pdf

Copyright

Disclaimer

Index of figures and tables